Side effects of CAR T-cell therapy


Author: Rebecca J

Category: Medical science

A new immunotherapy for lymphoma has been found to cause lower levels of neurologic toxicity than other T-cell therapies for lymphoma. The findings, reported January 20, 2020, in Nature Medicine, come from the first clinical test of a CAR T-cell therapy using a new anti-cancer T-cell receptor developed in CCR. The receptor targets the CD19 marker on the surface of cancerous B cells. More than half of the patients in this phase I trial experienced complete remissions after receiving the treatment.

CAR T-cell therapies are cancer treatments in which T cells from a patient’s blood are genetically manipulated so that they produce a synthetic receptor that improves their ability to recognize and destroy cancer cells. That receptor is known as a chimeric antigen receptor, or CAR.

Both FDA-approved CAR T-cell therapies for B-cell lymphoma use CARs that target CD19, a surface protein that cancerous B cells often express. Some patients experience complete remission of their cancer following this treatment. However, the treatment’s side effects can be severe. Many of the most significant problems are neurological, including speech problems, memory loss, tremors and seizures. Cytokine release syndrome (CRS), a potentially life-threatening inflammatory response, is less common but also a concern. These effects are thought to be triggered by CAR T cells’ release of substances called cytokines. 

The Journal of Cancer Clinical Trials aims to disseminate knowledge and promote discussion through the publication of peer-reviewed, high quality research papers on all topics related to Chromatography. The open access journal is published by OMICS International who hosts around 350 open access peer-reviewed journals as well as organizes more than 100 International scientific Conferences.

The Journal is successfully running in the 4th Volume which covers a wide variety of specialties including Cancer Surgery, Ovarian cancer, hepatitis infection, reaching out to analytical scientists worldwide. The Journal emphasizes high-level research and education. Original research articles, reviews, short communications, and letters to the editors in the fields of clinical trials are welcome. Every effort is made to have a speedy and critical peer-review process.

How we work: After submission, an acknowledgement with manuscript number is sent to the corresponding author within 7 working days. A 21 day window time frame is allotted for peer-review process wherein multiple experts are contacted. Author proof is generated within 7 working days after the acceptance decision.

Media Contact:

Rebecca J
Assistant Editorial Manager
Journal of Cancer Clinical Trials
Whatsapp No:  +1-504-608-2390